pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing. In the US, approximately 37.3

Insulin 130

Insulin Drugs Production Hormones 130

BioPharma Reporter

MAY 3, 2023

Protein drugs are notoriously difficult to deliver orally â but scientists have developed a new type of oral capsule that could deliver insulin and other similar drugs.

Insulin 52

Insulin Scientist Development Protein 52

Pharmaceutical Technology

JUNE 30, 2023

(Glucagon + insulin human)is under clinical development by Abvance Therapeutics and currently in Phase I for Hypoglycemia.

Insulin 100

Insulin Clinical Development Development 100

pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Pharmacy 105

Drug Discovery World

FEBRUARY 19, 2024

Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). Following this, blood glucose levels in the diabetic NHP began to fluctuate and increase markedly, and insulin injections needed to be resumed.

Insulin 52

Insulin Immune Response Engineer Antibody 52

BioPharma Reporter

NOVEMBER 21, 2022

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 98

Insulin Drug Delivery Development Drugs 98

pharmaphorum

JULY 14, 2021

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. . It was also responsible for the first recombinant insulin product – Humulin – which launched in 1982 and remains on sale.

Insulin 98

Insulin Protein Production Sales 98

pharmaphorum

OCTOBER 4, 2022

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, in combination with a dosing guide app. ONWARDS 6 is to assess the efficacy and safety of insulin icodec in 583 people with type 1 diabetes.

Insulin 59

Insulin Trials Clinical Trials Clinical Trials 59

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 276

Gene Editing Insulin Gene Licensing 276

pharmaphorum

JANUARY 12, 2023

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 59

Insulin Trials Development Drugs 59

BioPharma Reporter

JANUARY 29, 2024

Synthetic biology company rBIO has completed all required analytical characterizations of its insulin biosimilar, R-biolin.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

Drug Channels

JANUARY 9, 2024

There are also unusual formulary developments for insulin products, many of which experienced massive list price cuts for 2024. Unfortunately, the gross-to-net bubble will remain a fixture for this category, despite a price war led by almost half of the biosimilars. Read on for my deep dive into these two therapeutic categories.

Insulin 90

Insulin Pharmacy Drugs Production 90

pharmaphorum

JANUARY 25, 2023

The 501(c)3 non-profit Tidepool, which seeks to empower the next generation of innovations in diabetes management, has announced that the US Food and Drug Administration (FDA) has cleared Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in those six years old and above.

Insulin 59

Insulin Development Drugs Research 59

The Pharma Data

APRIL 28, 2022

Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin. events per patient year exposed to once-weekly insulin icodec and 0.27

Insulin 52

Insulin Trials Clinical Trials Clinical Trials 52

pharmaphorum

MARCH 2, 2022

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 52

Insulin Marketing Doctors Doctor 52

Scienmag

SEPTEMBER 29, 2021

Pancreatic beta cells produce, store and secrete insulin upon elevated blood glucose levels. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

In-Vivo 52

In-Vivo Insulin Development Regulation 52

Bio Pharma Dive

JULY 14, 2021

Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap.

Insulin 276

Insulin Development Drugs 276

pharmaphorum

SEPTEMBER 22, 2022

Insulin has been used to manage diabetes for a century, and while many advances have been made for people with both type 1 and type 2 diabetes – many more continue to be made. The post How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast appeared first on.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

BioSpace

AUGUST 19, 2020

Researchers from the Salk Institute took a major step forward in developing a new insulin-producing pancreatic cell cluster as a potential treatment for type 1 diabetes patients.

Development 139

Development Insulin Research 139

pharmaphorum

MAY 17, 2021

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. The initial therapeutic focus is diabetes, with three insulin-based products in development.

Insulin 52

Insulin Production Marketing Pharma Companies 52

XTalks

OCTOBER 13, 2021

Researchers at the University of Toledo have developed a vaccine against inflammatory arthritis that has shown promise in animal models. The potential cybersecurity risk associated with the remote controllers could under- or over-deliver insulin to patients if an unauthorized user hacks into the system.

Insulin 59

Insulin Life Science Vaccination Vaccine 59

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

Drug Channels

APRIL 3, 2024

There are also unusual formulary developments for insulin products, many of which experienced massive list price cuts for 2024. Unfortunately, the gross-to-net bubble will remain a fixture for this category, despite a price war led by almost half of the biosimilars. Read on for my deep dive into these two therapeutic categories.

Insulin 52

Insulin Pharmacy Drugs Production 52

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

Drug Discovery World

NOVEMBER 1, 2023

Previous spaceflight investigations indicate that growing crystals in space could yield a more uniform product with fewer imperfections, which can improve the drug discovery and development process. The post First spaceflight mission for drug development lab appeared first on Drug Discovery World (DDW).

Development 59

Development Drugs Insulin Branding 59

XTalks

FEBRUARY 2, 2023

The US Food and Drug Administration (FDA) has recently cleared for marketing an app called Tidepool Loop which can be used with compatible devices for automated insulin dosing (AID). The Tidepool loop app involves three integral parts: an integrated continuous glucose monitor (iCGM), a controller and an insulin pump.

Insulin 52

Insulin Marketing Life Science Development 52

Scienmag

MAY 17, 2022

Well known for their applications in the production of therapeutic proteins like insulin, plasmids are broadly used in the large-scale production of many bioproducts. These small, circular DNA molecules are used by scientists to introduce new genes into a target organism. Credit: CABBI Plasmids have extensive […].

Production 90

Production Insulin Development DNA 90

XTalks

FEBRUARY 24, 2021

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64

Insulin Production Drug Delivery Marketing 64

The Pharma Data

FEBRUARY 25, 2021

and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development. Lilly will commercialize the pen platform, which will include the new app and Lilly’s connected insulin pen solutions.

Insulin 40

Insulin Medicine Hormones Development 40

BioSpace

JULY 12, 2022

A multinational research collaboration has developed a new peptide dubbed “PATAS”, which appears to fix the metabolic abnormalities leading to type 2 diabetes (T2D).

Insulin 98

Insulin Development Research 98

BioSpace

JULY 13, 2021

No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.

Insulin 103

Insulin Development 103

Scienmag

NOVEMBER 9, 2021

A spectrum of conditions that includes coronary heart disease and diabetes, cardiometabolic disease typically impacts people who are obese, elderly, or insulin resistant. Decades after battling childhood cancer, survivors often face a new challenge: cardiometabolic disease. Credit: Laboratory of Molecular […].

Insulin 83

Insulin Development Medicine 83

Scienmag

DECEMBER 3, 2020

Researchers from the University of Copenhagen and biotech firm Gubra have developed a new insulin molecule that will make blood sugar regulation both easier and safer for those with type 1 diabetes Everyday life for the more than 46 million people around the world who suffer from type 1 diabetes could become much easier and […].

Insulin 40

Insulin Regulation Development Research 40

Pharmaceutical Technology

JUNE 10, 2023

RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

RZ-358 is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It was also under development for the treatment of insulinomas.

Insulin 100

Insulin Antibody Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 16, 2023

Despite such a broad range of pathologies, the commonality between them is the insulin response. dietary restriction) of the evolutionarily conserved insulin signalling pathway. These experiments demonstrated that the linkage between ageing and insulin was conserved up the evolutionary tree. Can we extend human life?

Insulin 130

Insulin DNA Genetics Life Science 130

pharmaphorum

NOVEMBER 8, 2022

The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart Button device that stores and transfers insulin dose-related data from the pen, and can link with compatible devices. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 64

Insulin Marketing Branding Manufacturing 64